Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F21%3A00078575" target="_blank" >RIV/00209805:_____/21:00078575 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/21:00121828

Result on the web

<a href="https://www.mdpi.com/2072-6694/13/7/1586" target="_blank" >https://www.mdpi.com/2072-6694/13/7/1586</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers13071586" target="_blank" >10.3390/cancers13071586</a>

Result language

angličtina

Original language name

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence

Original language description

Pathological complete response (pCR) achievement is undoubtedly the essential goal of neoadjuvant therapy for breast cancer, directly affecting survival endpoints. This retrospective study of 237 triple-negative breast cancer (TNBC) patients with a median follow-up of 36 months evaluated the role of adding platinum salts into standard neoadjuvant chemotherapy (NACT). After the initial four standard NACT cycles, early clinical response (ECR) was assessed and used to identify tumors and patients generally sensitive to NACT. BRCA1/2 mutation, smaller unifocal tumors, and Ki-67 GREATER-THAN OR EQUAL TO 65% were independent predictors of ECR. The total pCR rate was 41%, the achievement of pCR was strongly associated with ECR (OR = 15.1, p &lt; 0.001). According to multivariable analysis, the significant benefit of platinum NACT was observed in early responders GREATER-THAN OR EQUAL TO45 years, Ki-67 GREATER-THAN OR EQUAL TO 65% and persisted lymph node involvement regardless of BRCA1/2 status. Early responders with pCR had a longer time to death (HR = 0.28, p &lt; 0.001) and relapse (HR = 0.26, p &lt; 0.001). The pCR was achieved in only 7% of non-responders. However, platinum salts favored non-responders&apos; survival outcomes without statistical significance. Toxicity was significantly often observed in patients with platinum NACT (p = 0.003) but not for grade 3/4 (p = 0.155). These results based on real-world evidence point to the usability of ECR in NACT management, especially focusing on the benefit of platinum salts.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/LM2018125" target="_blank" >LM2018125: Bank of Clinical Samples</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancers

ISSN

2072-6694

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

7

Country of publishing house

CH - SWITZERLAND

Number of pages

19

Pages from-to

1586

UT code for WoS article

000638335700001

EID of the result in the Scopus database

2-s2.0-85103267338